Hopstem Biotech

Hopstem Biotechnology, founded in January 2017, is a clinical-stage company focused on developing induced pluripotent stem cell (iPSC)-derived therapies for central nervous system (CNS) disorders. The company was established by a team of neuroscientists and stem cell biologists from Johns Hopkins University, led by founder and CEO Dr. Jing Fan. Dr. Fan's background includes a bachelor's degree from Peking University, a Ph.D. in Neuroscience from the University of British Columbia, and postdoctoral training at Johns Hopkins University's Institute for Cell Engineering, giving her over 17 years of experience in neuroscience and pluripotent stem cells.

The company's core business revolves around its proprietary iPSC platform for neural differentiation and cell engineering. Hopstem's business model focuses on the in-house development and clinical translation of allogeneic, or universal, cell therapy products. The company has raised significant capital to advance its work, including a Series B financing round of nearly $40 million in 2021, with investors such as Lilly Asia Ventures and Hillhouse Investment Group. Its operations are supported by a 40,000-square-foot GMP manufacturing facility and R&D center in Hangzhou, China, and an office in the United States.

Hopstem's lead product candidate is hNPC01, an off-the-shelf injection of human forebrain neural progenitor cells. This therapy is designed to treat neurological damage by replacing lost cells and providing neurotrophic support to promote functional recovery. hNPC01 is being developed for patients with severe motor dysfunction resulting from chronic ischemic stroke and traumatic brain injury. A significant milestone was achieved in June 2023 when China's National Medical Products Administration (NMPA) granted Investigational New Drug (IND) approval for hNPC01 to enter clinical trials for chronic ischemic stroke. This was followed by an IND clearance from the U.S. Food and Drug Administration (FDA) in March 2024 for the same indication. The first patient in the Phase I trial was dosed in December 2023. Preliminary data from the ongoing study in China has shown a good safety profile and signs of efficacy, with patients showing clinically meaningful improvements in motor function. The company plans to initiate a U.S.-based Phase I/IIa clinical trial in 2025 and expects to complete the current Phase I study in June 2025.

Beyond its lead program, Hopstem is leveraging its platform to expand its pipeline. The company is exploring therapies for other CNS conditions like Alzheimer's, ALS, and autism. A strategic partnership with Neurophth Therapeutics was announced in June 2021 to co-develop iPSC-derived treatments for ocular diseases, further broadening the application of its core technology. Hopstem holds core patents for its technologies in China, the U.S., the European Union, and Japan.

Keywords: iPSC cell therapy, regenerative medicine, neurodegenerative diseases, central nervous system, chronic stroke treatment, traumatic brain injury, neural progenitor cells, hNPC01, allogeneic cell therapy, clinical-stage biotechnology, Johns Hopkins University, Jing Fan, GMP manufacturing, cell engineering, ocular diseases, IND approval, FDA, NMPA, clinical trials, stem cell biology